title: Response Assessment Criteria and Their Applications in Lymphoma: Part 1.
abstract: The effectiveness of cancer therapy, both in individual patients and across populations, requires a systematic and reproducible method for evaluating response to treatment. Early efforts to meet this need resulted in the creation of numerous guidelines for quantifying posttherapy changes in disease extent, both anatomically and metabolically. Over the past few years, criteria for disease response classification have been developed for specific cancer histologies. To date, the spectrum of disease broadly referred to as lymphoma is perhaps the most common for which disease response classification is used. This review article provides an overview of the existing response assessment criteria for lymphoma and highlights their respective methodologies and validities. Concerns over the technical complexity and arbitrary thresholds of many of these criteria, which have impeded the long-standing endeavor of standardizing response assessment, are also discussed.
authors.affiliation: Stanford University Medical Center, Stanford, California.
authors.forename: Mateen C
authors.initials: MC
authors.lastname: Moghbel
authors.affiliation: Mount Sinai Medical Center, New York, New York.
authors.forename: Lale
authors.initials: L
authors.lastname: Kostakoglu
authors.affiliation: McMaster University, Hamilton, Ontario, Canada.
authors.forename: Katherine
authors.initials: K
authors.lastname: Zukotynski
authors.affiliation: Washington University, St. Louis, Missouri.
authors.forename: Delphine L
authors.initials: DL
authors.lastname: Chen
authors.affiliation: University of British Columbia, Vancouver, British Columbia, Canada; and.
authors.forename: Helen
authors.initials: H
authors.lastname: Nadel
authors.affiliation: Kaiser Permanente, Santa Clara, California.
authors.forename: Ryan
authors.initials: R
authors.lastname: Niederkohr
authors.affiliation: Stanford University Medical Center, Stanford, California erik.mittra@stanford.edu.
authors.forename: Erik
authors.initials: E
authors.lastname: Mittra
mesh_terms: D006801:Humans; D008223:Lymphoma / Q000628:therapy*; D016896:Treatment Outcome
keywords: CT; PERCIST; PET; RECIST; lymphoma